ccl23 protein  (Boster Bio)

Journal: Cancers

Article Title: Ovarian Cancer Ascites Enriched for CCL23 Reduces Macrophage-Derived CXCL10 Secretion and Is Associated with Poor Patient Outcomes

doi: 10.3390/cancers17243925

Figure Lengend Snippet: CCL23 is present in all human ascites samples with primary or recurrent ovarian cancer. ( A ) The distribution of CCL23 concentration (ng/mL) in ovarian cancer ascites samples ( n = 40). ( B ) Low ( n = 17), intermediate ( n = 12), and high ( n = 11) CCL23 ascites concentrations. Data presented as mean ± S.E.M. ANOVA with Bonferroni post hoc test performed for significance; * p < 0.05. ( C ) Kaplan–Meier survival curves (log-rank) of patient outcome data from low ( n = 17; gray line), intermediate ( n = 12; light gray line), and high ( n = 11; red line) CCL23 concentrations.

Article Snippet: Cell-free supernatant was harvested from serum-starved cells incubated with vehicle, CCL23 aa22-120 (Peprotech, East Windsor, NJ, USA; 300-29) or CCL23 aa46-120 (R&D Systems, Minneapolis, MN, USA; 131-M1-025) peptides for 30 min, or the signal transducer and activator of transcription (STAT-3) inhibitor NSC 74859 (100 μM; Tocris; Minneaoplis, MN, USA; 4655) was reconstituted and serum-starved cells were incubated with 100 μM NSC 74859 for 30 min [ ] prior to incubation with CCL23.

Techniques: Concentration Assay

Journal: Cancers

Article Title: Ovarian Cancer Ascites Enriched for CCL23 Reduces Macrophage-Derived CXCL10 Secretion and Is Associated with Poor Patient Outcomes

doi: 10.3390/cancers17243925

Figure Lengend Snippet: High CXCL10 levels correlate with low CCL23 concentrations in ovarian ascites. ( A ) Quantification of C-X-C Motif Chemokine Ligand 10 (CXCL10) cytokine concentration from ovarian ascites patient samples containing low ( n = 17), intermediate ( n = 12), and high ( n = 11) CCL23. Data presented as mean ± S.E.M. Statistical analyses performed using one-way ANOVA with Dunnet’s post hoc test for significance; * p < 0.05. ( B ) Pearsons linear regression of CXCL10 versus CCL23 concentrations indicated a significant negative association between (F(1,38) = 4.86, p = 0.033).

Article Snippet: Cell-free supernatant was harvested from serum-starved cells incubated with vehicle, CCL23 aa22-120 (Peprotech, East Windsor, NJ, USA; 300-29) or CCL23 aa46-120 (R&D Systems, Minneapolis, MN, USA; 131-M1-025) peptides for 30 min, or the signal transducer and activator of transcription (STAT-3) inhibitor NSC 74859 (100 μM; Tocris; Minneaoplis, MN, USA; 4655) was reconstituted and serum-starved cells were incubated with 100 μM NSC 74859 for 30 min [ ] prior to incubation with CCL23.

Techniques: Concentration Assay

Journal: Cancers

Article Title: Ovarian Cancer Ascites Enriched for CCL23 Reduces Macrophage-Derived CXCL10 Secretion and Is Associated with Poor Patient Outcomes

doi: 10.3390/cancers17243925

Figure Lengend Snippet: In silico analysis of patient outcomes differs based on tumor expression levels of CCL23 and CXCL10. Kaplan–Meier overall survival analyses were performed on stage III and IV ovarian cancer patients, histology agnostic ( n = 1081, http://kmplot.com ), using datasets hosted in the Cancer Genome Atlas (TCGA). Patients were stratified based on the quantile expression of high (red line) versus low (black line) ( A ) CCL23 mRNA or ( B ) CXCL10 mRNA expression from ovarian tumors. Log-rank and Cox hazards tests were performed for statistical significance.

Article Snippet: Cell-free supernatant was harvested from serum-starved cells incubated with vehicle, CCL23 aa22-120 (Peprotech, East Windsor, NJ, USA; 300-29) or CCL23 aa46-120 (R&D Systems, Minneapolis, MN, USA; 131-M1-025) peptides for 30 min, or the signal transducer and activator of transcription (STAT-3) inhibitor NSC 74859 (100 μM; Tocris; Minneaoplis, MN, USA; 4655) was reconstituted and serum-starved cells were incubated with 100 μM NSC 74859 for 30 min [ ] prior to incubation with CCL23.

Techniques: In Silico, Expressing

Journal: Cancers

Article Title: Ovarian Cancer Ascites Enriched for CCL23 Reduces Macrophage-Derived CXCL10 Secretion and Is Associated with Poor Patient Outcomes

doi: 10.3390/cancers17243925

Figure Lengend Snippet: In vitro stimulation of immune cells with CCL23 reduces CXCL10 secretion. ( A ) Immunohistochemical staining of differentiated THP-1 monocytes for the C-C motif chemokine receptor 1 (CCR1; red); nuclei stained with DAPI (blue). Scale bar = 200 μm. ( B ) Secondary antibody only staining control. ( C ) qRT-PCR assessment of gene expression for CCR1 in HEL ( n = 3) and THP-1 cells ( n = 3). ( D ) Quantification of C-X-C Motif Chemokine Ligand 10 (CXCL10) cytokine concentrations from cell-free supernatant of treated THP-1 cells represented as fold-change normalized to vehicle control ( n = 3 per group). Cells were stimulated with either vehicle, CCL23 peptides (aa22-120 and aa46-120; 100 ng/mL, 30 min), or the signal transducer and activator of transcription (STAT-3) inhibitor NSC 74859 (100 μM) followed by CCL23. Data presented as mean ± S.E.M., n = 3 separate experiments. Statistical analyses performed using t -test or one-way ANOVA with Bonferroni post hoc test for significance; * p < 0.05.

Article Snippet: Cell-free supernatant was harvested from serum-starved cells incubated with vehicle, CCL23 aa22-120 (Peprotech, East Windsor, NJ, USA; 300-29) or CCL23 aa46-120 (R&D Systems, Minneapolis, MN, USA; 131-M1-025) peptides for 30 min, or the signal transducer and activator of transcription (STAT-3) inhibitor NSC 74859 (100 μM; Tocris; Minneaoplis, MN, USA; 4655) was reconstituted and serum-starved cells were incubated with 100 μM NSC 74859 for 30 min [ ] prior to incubation with CCL23.

Techniques: In Vitro, Immunohistochemical staining, Staining, Control, Quantitative RT-PCR, Gene Expression

Journal: Clinical Proteomics

Article Title: ARTN and CCL23 predicted chemosensitivity in acute myeloid leukemia: an Olink ® proteomics approach

doi: 10.1186/s12014-025-09527-7

Figure Lengend Snippet: Immunohistochemical (IHC) staining and mRNA expression of candidate expression in acute myeloid leukemia (AML) patient specimens. ( A ) Representative images of IHC staining for ATRN, CCL23, and CCL13 (×400), showing sections from patients with complete remission (CR) at the top and non-CR at the bottom. ( B ) The bar graph illustrates the percentage of patients showing strong staining intensity (3+) for each antibody. It compares the proportions of CR and non-CR group patients with strong staining. A t-test determined the statistical significance of differences in staining intensity between the CR and non-CR groups, indicated by * p < 0.05. ( C ) The Log2 (CPM) expression levels of ARTN and CCL23 from bulk RNA-seq analysis comparing CR and non-CR groups in acute myeloid leukemia patients are shown. The box plot represents the 25th and 75th percentiles, with whiskers indicating the maximum and minimum values. Solid lines within the boxes mark the medians. Statistical significance is denoted by * p < 0.05 and ** p < 0.01. ( D ) The Human Protein Atlas data show that ARTN and CCL23 are expressed at significantly higher levels ( p < 0.001) in AML patients compared to those with other cancers

Article Snippet: We also utilized the Human Protein Atlas [ ] for external validation, demonstrating that ARTN (median: 0.983 NPX, n = 48) and CCL23 (median: 2.455 NPX, n = 48) were expressed at significantly higher levels ( p < 0.001) in AML patients compared to those with other cancers (Fig. D and supplementary Table ).

Techniques: Immunohistochemical staining, Immunohistochemistry, Expressing, Staining, RNA Sequencing

Journal: Clinical Proteomics

Article Title: ARTN and CCL23 predicted chemosensitivity in acute myeloid leukemia: an Olink ® proteomics approach

doi: 10.1186/s12014-025-09527-7

Figure Lengend Snippet: “7 + 3” induction response prediction by high ARTN and CCL23 expressions

Article Snippet: We also utilized the Human Protein Atlas [ ] for external validation, demonstrating that ARTN (median: 0.983 NPX, n = 48) and CCL23 (median: 2.455 NPX, n = 48) were expressed at significantly higher levels ( p < 0.001) in AML patients compared to those with other cancers (Fig. D and supplementary Table ).

Techniques: